Talvey
talquetamab
Table of contents
Overview
Talvey is a cancer medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has come back (relapsed) and has not responded to treatment (refractory).
It is used in patients who have received at least three previous therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose disease has worsened since the last treatment.
Multiple myeloma is rare, and Talvey was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 20 August 2021. Further information on the orphan designation can be found on the EMA website.
Talvey contains the active substance talquetamab.
-
List item
Talvey : EPAR - Medicine overview (PDF/110.51 KB)
First published: 21/09/2023
EMA/379931/2023 -
-
List item
Talvey : EPAR - Risk management plan (PDF/368.47 KB)
First published: 21/09/2023
Authorisation details
Product details | |
---|---|
Name |
Talvey
|
Agency product number |
EMEA/H/C/005864
|
Active substance |
talquetamab
|
International non-proprietary name (INN) or common name |
talquetamab
|
Therapeutic area (MeSH) |
Multiple Myeloma
|
Anatomical therapeutic chemical (ATC) code |
L01FX29
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Conditional approval |
This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation. |
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Janssen-Cilag International N.V.
|
Revision |
1
|
Date of issue of marketing authorisation valid throughout the European Union |
21/08/2023
|
Contact address |
Turnhoutseweg 30 |
Product information
23/11/2023 Talvey - EMEA/H/C/005864 - IB/0001/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti CD38 antibody and have demonstrated disease progression on the last therapy.